-
-
-
-
-
-
-
Cognition Therapeutics, Inc. (CGTX) Tops Q3 EPS by 4c
-
-
-
-
-
-
-
Cognition Therapeutics (CGTX) Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target
-
-
-
-
-
-
-
Cognition Therapeutics (CGTX) to Report Biomarker Results from Phase 2 SHINE Study
-
-
-
-
-
-
-
Cognition Therapeutics (CGTX) PT Raised to $6 at H.C. Wainwright
-
-
-
-
-
-
-
Cognition Therapeutics, Inc. (CGTX) Tops Q2 EPS by 5c
-
-
-
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

